Skip to main content

Lutathera in Somatostatin Neuroendocrine Tumors

Lutathera in Somatostatin Neuroendocrine Tumors

Contact

If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is now recruiting. Learn more about enrolling here.

Description

This study involves taking a study drug called Lutathera.The overall goal of this study is to see if Lutathera is safe in adolescentsubjects with either a gastroenteropancreatic neuroendocrine tumor (GEP-NET),or a pheochromocytoma and/or paraganglioma (PPGL). This study will also look atthe levels of radioactivity after Lutathera administration.

Eligibility and criteria


IRB Number:
21-018820
Eligible age range:
12 years - 17 years
Clinical trial phase:
Phase II
Official title:
A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

What to expect

This study will enroll male and female patients between 12and 18 years of age that have been diagnosed with either agastroenteropancreatic neuroendocrine tumor (GEP-NET), or a pheochromocytomaand/or paraganglioma (PPGL) that has spread (metastasized) or cannot becompletely removed by surgery.  Subjects will receive Lutathera viaintravenous (IV) infusion. Lutathera is a drug that is taken up by GEP-NETs andPPGLs and emits radiation to attempt to prevent growth of the cancer cells. To protect the kidneys from radiation, an amino acid solution will alsobe administered with each Lutathera dose. Study visits will also include thefollowing assessments: electrocardiograms (ECGs), urine tests, blood tests,SPECT/CT imaging, and whole body planar imaging.

 
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.

Jump back to top